Med-Chemist

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label HER2- Metastatic Breast Cancer. Show all posts
Showing posts with label HER2- Metastatic Breast Cancer. Show all posts
Wednesday, June 5, 2019

FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

›
In continuation of my update on palbociclib Pfizer  announced that the U.S. Food and Drug Administration (FDA) approved a suppleme...
Friday, May 27, 2016

Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR , HER2- Metastatic Breast Cancer

›
  Palbociclib  (codenamed  PD-0332991 , trade name  Ibrance ) Pfizer Inc.,  announced that the U.S. Food and Drug Administration (...
Friday, May 13, 2016

Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR , HER2- Metastatic Breast Cancer

›
In continuation of my updates on palbociclib Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) h...
Wednesday, May 11, 2016

Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR , HER2- Metastatic Breast Cancer

›
In continuation of my updates on palbociclib Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) h...
›
Home
View web version

Contributors

  • Dr. Umesh..
  • https://www.med-chemist.com
Powered by Blogger.